WINTON GROUP Ltd Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

WINTON GROUP Ltd bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,688 shares of the biotechnology company’s stock, valued at approximately $425,000.

Other hedge funds also recently bought and sold shares of the company. Capital International Investors increased its stake in Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after acquiring an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC increased its position in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the period. Norges Bank purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $80,697,000. Bank of Nova Scotia purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $50,990,000. Finally, Avoro Capital Advisors LLC lifted its stake in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after buying an additional 319,444 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on SRPT. UBS Group boosted their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird raised their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, June 21st. Citigroup dropped their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. BMO Capital Markets raised their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, September 6th. Three equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $187.39.

Insiders Place Their Bets

In other news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,801 shares of company stock valued at $8,399,586. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Trading Down 0.5 %

Shares of SRPT opened at $125.01 on Thursday. The firm’s 50 day simple moving average is $138.75 and its 200 day simple moving average is $132.67. The company has a market capitalization of $11.82 billion, a P/E ratio of 1,145.00 and a beta of 0.81. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business’s revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.27) earnings per share. Sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.